Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116863) titled 'A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Kyungdong Pharmaceutical Co., Ltd.
Condition:
Essential Hypertension
Intervention:
Drug: KDF1901-R0
Drug: KDF1901-L
Drug: KDF1901
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: June 21, 2022
Target Sample Size: 286
Countries of Re...